Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Pharmaceutical Research
Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
Drug Development and Industrial Pharmacy
289 One limitation of ASNase therapy, which promotes tumor cell death by systematically lowering the asparagine concentration, is that it impairs ASN requirements in normal immune cells
For example, laboratory work by Santra et al
The variables become hopelessly confounded
US$ 27.93
US$ 29.22
US$ 28.40
US$ 22.46
US$ 27.05
